These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 24957315)
1. Safety of standard-dose (.9-mg/kg) alteplase intravenous thrombolysis for acute ischemic stroke in Afro-Caribbeans, French West Indies. Chausson N; Olindo S; Joux J; Saint-Vil M; Aveillan M; Smadja D J Stroke Cerebrovasc Dis; 2014 Aug; 23(7):1776-80. PubMed ID: 24957315 [TBL] [Abstract][Full Text] [Related]
2. Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study. Wang X; Song L; Yang J; Sun L; Moullaali TJ; Sandset EC; Delcourt C; Lindley RI; Robinson TG; Minhas JS; Arima H; Chalmers J; Kim JS; Sharma V; Wang JG; Pontes-Neto O; Lavados PM; Olavarría VV; Lee TH; Levi C; Martins SO; Thang NH; Anderson CS; Cerebrovasc Dis; 2019; 48(3-6):207-216. PubMed ID: 31812956 [TBL] [Abstract][Full Text] [Related]
3. Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety. Zhao G; Huang T; Zheng M; Cui Y; Liu Y; Cheng Z; Wang Z Eur Neurol; 2018; 79(1-2):68-73. PubMed ID: 29241193 [TBL] [Abstract][Full Text] [Related]
4. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. Thomalla G; Simonsen CZ; Boutitie F; Andersen G; Berthezene Y; Cheng B; Cheripelli B; Cho TH; Fazekas F; Fiehler J; Ford I; Galinovic I; Gellissen S; Golsari A; Gregori J; Günther M; Guibernau J; Häusler KG; Hennerici M; Kemmling A; Marstrand J; Modrau B; Neeb L; Perez de la Ossa N; Puig J; Ringleb P; Roy P; Scheel E; Schonewille W; Serena J; Sunaert S; Villringer K; Wouters A; Thijs V; Ebinger M; Endres M; Fiebach JB; Lemmens R; Muir KW; Nighoghossian N; Pedraza S; Gerloff C; N Engl J Med; 2018 Aug; 379(7):611-622. PubMed ID: 29766770 [TBL] [Abstract][Full Text] [Related]
5. Clinical implication of hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. Ho BL; Chen CF; Lin RT; Liu CK; Chao AC Neurol Sci; 2016 Nov; 37(11):1799-1805. PubMed ID: 27423451 [TBL] [Abstract][Full Text] [Related]
6. Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial. Minhas JS; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Donnan GA; Kim JS; Lavados PM; Lee TH; Martins SCO; Olavarría VV; Pandian JD; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Thang NH; Wang JG; Woodward M; Chalmers J; Anderson CS; Robinson TG; Cerebrovasc Dis; 2018; 45(5-6):213-220. PubMed ID: 29705803 [TBL] [Abstract][Full Text] [Related]
7. Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke. Anderson CS; Robinson T; Lindley RI; Arima H; Lavados PM; Lee TH; Broderick JP; Chen X; Chen G; Sharma VK; Kim JS; Thang NH; Cao Y; Parsons MW; Levi C; Huang Y; Olavarría VV; Demchuk AM; Bath PM; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Ricci S; Roffe C; Pandian J; Billot L; Woodward M; Li Q; Wang X; Wang J; Chalmers J; N Engl J Med; 2016 Jun; 374(24):2313-23. PubMed ID: 27161018 [TBL] [Abstract][Full Text] [Related]
8. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study. Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M; J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972 [TBL] [Abstract][Full Text] [Related]
9. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study). Robinson TG; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Demchuk AM; Donnan GA; Kim JS; Lavados PM; Lee TH; Lindley RI; Martins SCO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Nguyen TH; Wang JG; Woodward M; Chalmers J; Anderson CS; Stroke; 2017 Jul; 48(7):1877-1883. PubMed ID: 28619989 [TBL] [Abstract][Full Text] [Related]
10. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. Kono S; Deguchi K; Morimoto N; Kurata T; Yamashita T; Ikeda Y; Narai H; Manabe Y; Takao Y; Kawada S; Kashihara K; Takehisa Y; Inoue S; Kiriyama H; Abe K J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462 [TBL] [Abstract][Full Text] [Related]
11. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. Hacke W; Kaste M; Bluhmki E; Brozman M; Dávalos A; Guidetti D; Larrue V; Lees KR; Medeghri Z; Machnig T; Schneider D; von Kummer R; Wahlgren N; Toni D; N Engl J Med; 2008 Sep; 359(13):1317-29. PubMed ID: 18815396 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Micieli G; Marcheselli S; Tosi PA Vasc Health Risk Manag; 2009; 5(1):397-409. PubMed ID: 19475777 [TBL] [Abstract][Full Text] [Related]
13. Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study. Kim BJ; Han MK; Park TH; Park SS; Lee KB; Lee BC; Yu KH; Oh MS; Cha JK; Kim DH; Lee J; Lee SJ; Ko Y; Park JM; Kang K; Cho YJ; Hong KS; Kim JT; Choi JC; Kim DE; Shin DI; Kim WJ; Lee J; Lee JS; Yoon BW; Gorelick PB; Bae HJ Stroke; 2015 Sep; 46(9):2541-8. PubMed ID: 26243232 [TBL] [Abstract][Full Text] [Related]
14. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Mehta RH; Cox M; Smith EE; Xian Y; Bhatt DL; Fonarow GC; Peterson ED; Stroke; 2014 Aug; 45(8):2263-9. PubMed ID: 25070958 [TBL] [Abstract][Full Text] [Related]
15. The Risk of Hemorrhagic Transformation After Thrombolysis for Acute Ischemic Stroke in Chinese Versus North Americans: A Comparative Study. Xu X; Wang D; Wang F; Norton C; Liu X; Selim M J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):2381-2387. PubMed ID: 29778315 [TBL] [Abstract][Full Text] [Related]
16. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341 [TBL] [Abstract][Full Text] [Related]
17. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Seet RC; Rabinstein AA Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870 [TBL] [Abstract][Full Text] [Related]
18. Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis. Carr SJ; Wang X; Olavarria VV; Lavados PM; Rodriguez JA; Kim JS; Lee TH; Lindley RI; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Woodward M; Chalmers J; Anderson CS; Robinson TG; Stroke; 2017 Sep; 48(9):2605-2609. PubMed ID: 28739832 [TBL] [Abstract][Full Text] [Related]
20. Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012. Tong X; George MG; Yang Q; Gillespie C Int J Stroke; 2014 Aug; 9(6):728-34. PubMed ID: 24024962 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]